Investing.com - Cyclo Therapeutics (NASDAQ: CYTH) reported first quarter EPS of $-0.26, $0.05 worse than the analyst estimate of $-0.21. Revenue for the quarter came in at $311K versus the consensus estimate of $169K.
Cyclo Therapeutics's stock price closed at $1.60. It is down -11.60% in the last 3 months and up 44.14% in the last 12 months.
Cyclo Therapeutics saw positive EPS revisions and negative EPS revisions in the last 90 days. See Cyclo Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Cyclo Therapeutics's Financial Health score is "weak performance".
Check out Cyclo Therapeutics's recent earnings performance, and Cyclo Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar